Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety

BACKGROUND: This phase II neoadjuvant study evaluated the efficacy and safety of a triweekly regimen of docetaxel and carboplatin in combination with trastuzumab (TCbH) in Japanese women with human epidermal growth factor receptor type2 (HER2)-positive primary breast cancer. METHODS: Patients with H...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugitani, Ikuko, Ueda, Shigeto, Sakurai, Takashi, Shigekawa, Takashi, Hirokawa, Eiko, Shimada, Hiroko, Takeuchi, Hideki, Matsuura, Kazuo, Misumi, Misono, Fujiuchi, Nobuko, Takahashi, Takao, Hasebe, Takahiro, Osaki, Akihiko, Saeki, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608788/
https://www.ncbi.nlm.nih.gov/pubmed/28547525
http://dx.doi.org/10.1007/s10147-017-1136-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608788/
https://www.ncbi.nlm.nih.gov/pubmed/28547525
http://dx.doi.org/10.1007/s10147-017-1136-8

Ejemplares similares